This patent covers the administration of mesenchymal stem cells as "facilitator cells" such that engraftment of hematopoietic stem cells is accelerated. Mesenchymal stem cells may play this engraftment assisting role due to the wide variety of growth factors that they are known to produce.
This is one of the original Osiris patents covering the therapeutic use of mesenchymal stem cells. In this patent mesenchymal stem cells are generated from the bone marrow and used to regenerate connective tissue such as bone or cartilage.
This patent teaches the use of mesenchymal stem cells to promote engraftment of hematopoietic stem cells. I wonder how this mesenchymal cell population is different that the stromal cell populations that are also used to promote engraftment?
This patent is assigned to Amrad, a company whose patents have recently been used to challenge the WARF patents. The current patent involves the use of LIF in enhancing ability of implanted embryos to develop into normal offspring. The relevance of this patent to embryonic stem cells is that LIF has been used...
This is one of the patents on the human SCID mouse. It teaches methods of introducing human stem cells into a mouse that is immune compromized, so that the behaviour of human stem cells can be studied in a non-human model.
This patent is part of the huge wall Amgen put around the IP for stem cell factor. This patent specifically encompasses the cells that are transformed with SCF genes in order to generate SCF protein. SCR is the same as kit ligand.
This patent teaches ways of expanding stem cell, including culture in IL-6 and GM-CSF.
This patent covers transfection of stromal cells with therapeutic genes and administering the transfected cells into a recipient in need of therapy. It is interesting to see if these stromal cells have a similar phenotype as the mesenchymal stem cells that Osiris has patents on.
This patent covers the use of stromal cells for delivery of genes. Stromal cells can migrate systemically and when transfected with genes can serve as a stable source of protein production in a patient. I wonder what the difference is between the stromal cells described in this patent and the mesenchymal stem cells covered by Osiris?
This patent teaches ways to increase hematopoiesis through administration of some chemical compositions. The patent has 2 independent claims that essentially cover these compositions. This seems like an interesting patent but I need to actually look up and see if these compositions have been developed or not.